We propose this study as a future starting point for a more substantial analysis of the correlation between response to ALK inhibitors and BMI status, also exploiting possible correlation with metabolic syndrome and molecular subtypes of lung cancer. The gene discussed is ALK; the disease is metabolic syndrome.